跳至主要内容
临床试验/NCT00080054
NCT00080054已完成1 期

Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Temozolomide for Treatment of Malignant Gliomas

Pharmacyclics LLC.2 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2004年3月23日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
2

研究概览

简要总结

The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temozolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years old
  • Histologically confirmed diagnosis of malignant gliomas that requires systemic antineoplastic treatment. Malignant glioma is defined as any of the following: Glioblastoma multiforme (GBM); Anaplastic astrocytoma (AA); Anaplastic oligodendroglioma; Anaplastic mixed glioma; Glioma not otherwise specified (except low-grade glioma)
  • ECOG performance status score of 0, 1, or 2
  • Each patient must sign a study-specific informed consent form

排除标准

  • Laboratory values of:
  • Absolute neutrophil count < 2000/µL
  • Platelet count < 100,000/µL
  • AST or ALT > 2 x the upper limit of normal (ULN)
  • Alkaline phosphatase > 5 x ULN
  • Bilirubin > 2 x ULN
  • Creatinine > 2.0 mg/µL
  • Plan to use any additional cancer therapy (e.g., systemic, radiation, surgery) during the study period
  • Women who are pregnant or lactating

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验